chartexchange

Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewswire Inc. | Nov 10, 2026 7:00 AM EST

Dosed first participant in Phase 1 clinical trial of HMB-003 for management of heavy menstrual bleeding, a condition affecting more than 23 million women in the U.S. alone

Read original article